{{ $ActivityName }}
Hypoglycaemia
Weight gain
Beta-cell Loss
Others
Moderate to high
Moderate
Very high
High
5-10 years
11-15 years
16-20 years
>20 years
Early
Late
Yes
No
SGLT2i
DPP4i
Drugs in combination should have different mechanisms of action.
The pharmacokinetics of drugs must not be too different from each other.
The combination can be chosen based on the recommendations of treatment guidelines.
Reduced pill burden
Reduced medication error
Allows drugs with synergistic combination
Low cost to patient
Simplified dosing
Targeting various pathophysiological factors as never before
Ensuring durable glycaemic controls with preservation of beta cell mass
Good possibility of additional cardio-renal protection
Monotherapy
Dual FDC
Triple FDC
Individual Drugs Prescribed Separately